Untested, unapproved compounded hormone prescriptions reach 26 to 33 million a year

(The North American Menopause Society (NAMS)) The number of prescriptions for mostly unregulated compounded hormone therapy for women at menopause has reached an estimated 26 to 33 million a year. That approaches the 36 million prescriptions per year for well-regulated and tested FDA-approved hormone therapy, shows an analysis of the market compounded hormone therapy market, published online this month in Menopause, the journal of the North American Menopause Society.